Rahul Singhvi, Resilience CEO
August 24, 2022 01:09 PM EDT
Cell/Gene Tx
Manufacturing

Re­silience part­ners with the Cal­i­for­nia In­sti­tute for Re­gen­er­a­tive Med­i­cine to help cell ther­a­py star­tups

Tyler Patchen

News Reporter

As Re­silience keeps up the mo­men­tum post-Se­ries D, the bio­man­u­fac­tur­er has reeled in an­oth­er part­ner­ship, this time in the Gold­en State.

The com­pa­ny an­nounced that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times